September 17th, 2010
FDA Grants Expanded Indication to CRT-D Devices
Larry Husten, PHD
The FDA has expanded the indication for CRT-D devices made by Boston Scientific. Previously, the devices had been approved only in NYHA Class III and IV patients. The expanded indication now includes Class I and II patients who have left bundle branch block. The expanded indication is based on data from the MADIT-CRT trial.
“This approval allows heart failure patients with left bundle branch block to benefit from this therapy,” said Jeffrey Shuren, director of the FDA’s Center for Devices and Radiological Health, in an FDA press release. “The FDA is pleased to safely make this new technology available for a greater number of heart failure patients.”
One Response to “FDA Grants Expanded Indication to CRT-D Devices”
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?
Why would the Boston Scientific device be any different than other CRT-D devises in helping this patient population? The indication should be for all CRT-D devices and not manufacture specific.
Competing interests pertaining specifically to this post, comment, or both:
Research with St Jude Medical